Allogeneic Stem Cell Transplantation Clinical Trial
Official title:
Recombinant Human Growth Hormone(RH-GH) For Accelerating Immune Reconstitution In Pediatric and Adult Patients Undergoing Allogeneic Stem Cell Transplantation
The primary objective of this study is to define the safety and efficacy of recombinant human growth hormone (rh-GH, Genotropin) in a patients undergoing allogeneic transplantation.
The primary objective of this study is to define the safety and efficacy of recombinant human growth hormone (rh-GH, Genotropin) in a population of patients undergoing allogeneic stem cell transplant. The secondary objectives of this study are: to evaluate the incidence of mortality due to opportunistic infections in the first 6 months, to evaluate the incidence and severity of infectious complications, to assess laboratory parameters of post-transplant immune recovery in patients on GH therapy and to determine the probability and time of neutrophil and platelet recovery on GH therapy. ;
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05443854 -
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
|
Phase 3 | |
| Not yet recruiting |
NCT01212796 -
Allo After Allo Stem Cell Transplantation Following Relapse After Allogeneic Transplant in Haematological Malignancies: Retrospective Results of the GETH
|
N/A | |
| Terminated |
NCT01185223 -
Study Comparing Valganciclovir Versus Ganciclovir in Patients Following Allogeneic Stem Cell Transplantation
|
Phase 3 | |
| Recruiting |
NCT06028828 -
Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation
|
Phase 2 | |
| Not yet recruiting |
NCT03964922 -
Immunoevasive Tactics Employed by Myeloid Malignancy After Allogeneic Stem Cell Transplantation
|
N/A | |
| Completed |
NCT03467074 -
Role of Interferon-λ and Vaccine Response
|
||
| Completed |
NCT02273024 -
Exercise Prior to Allogeneic Hematologic Stem Cell Transplantation
|
N/A | |
| Recruiting |
NCT06093334 -
Imaging of Chemotherapy-induced Morphological and Functional Lung Changes in Childhood ALL and HD
|
N/A | |
| Recruiting |
NCT03286530 -
Ruxolitinib + Allogeneic Stem Cell Transplantation in AML
|
Phase 2 | |
| Completed |
NCT01092026 -
Unrelated Umbilical Cord Blood Transplantation With Coinfusion of Mesenchymal Stem Cells
|
N/A | |
| Recruiting |
NCT00883714 -
Exercise During the Allogeneic Stem Cell Transplantation
|
Phase 3 | |
| Recruiting |
NCT01160952 -
Long-term Versus Short-term Sequential Therapy (Intravenous Itraconazole Followed by Oral Solution) of Itraconazole as Primary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation
|
Phase 2 | |
| Completed |
NCT04628338 -
IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation
|
Early Phase 1 | |
| Completed |
NCT06256341 -
HHV-6-specific T-cell Reconstitution Among Children and Adolescents After Allogeneic Stem.
|
||
| Completed |
NCT05088941 -
Impact of COVID-19 Pandemic on Allogeneic Stem Cell Transplantation Organization : a French Experience
|
||
| Not yet recruiting |
NCT06453460 -
Prospect Eval of Efficacy of CMV-TCIP Direct Letermovir Prophylax After Allogen Hemato Cell Transpla
|
Phase 2 | |
| Recruiting |
NCT02533947 -
Cognition in Allogeneic Stem Cell Transplanted Patients and Sports
|
N/A | |
| Completed |
NCT01560689 -
Inhaled BUDESONIDE/FORMOTEROL in Bronchiolitis Obliterans Following Stem Cell Transplantation
|
Phase 2 | |
| Not yet recruiting |
NCT06297629 -
A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation
|
Phase 2 | |
| Completed |
NCT01929980 -
Bortezomib to Treat Significant Complication of HSCT
|
Phase 2 |